Zurcher Kantonalbank (Zurich Cantonalbank) Cara Therapeutics, Inc. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 01, 2023	BUY	$8.88 - $12.77 $15,309 - $22,015	1,724 Added 29.29%	7,610 $81,000
Q1 2022 Apr 21, 2022	SELL	$9.94 - $12.65 $42,950 - $54,660	-4,321 Reduced 42.33%	5,886 $72,000
Q4 2021 Feb 01, 2022	SELL	$11.99 - $18.14 $5,239 - $7,927	-437 Reduced 4.11%	10,207 $124,000
Q3 2021 Nov 15, 2021	BUY	$11.55 - $16.06 $1,536 - $2,135	133 Added 1.27%	10,644 $164,000
Q2 2021 Jul 30, 2021	BUY	$12.38 - $29.19 $57,257 - $135,003	4,625 Added 78.58%	10,511 $150,000
Q2 2020 Jul 28, 2020	BUY	$12.39 - $17.33 $42,522 - $59,476	3,432 Added 139.85%	5,886 $101,000
Q1 2019 Apr 29, 2019	SELL	$14.41 - $19.64 $16,528 - $22,527	-1,147 Reduced 31.85%	2,454 $48,000
Q4 2018 Jan 25, 2019	BUY	$12.45 - $23.47 $12,001 - $22,625	964 Added 36.56%	3,601 $47,000
Q2 2018 Aug 06, 2018	SELL	$11.6 - $19.27 $19,511 - $32,412	-1,682 Reduced 38.94%	2,637 $50,000
Q4 2017 Jan 31, 2018	BUY	$11.86 - $14.08 $51,223 - $60,811	4,319	4,319 $53,000

Others Institutions Holding CARA

# of Institutions

Shares Held

12.8M

Call Options Held

Put Options Held

Vanguard Group Inc Valley Forge, PA

2.25M
Shares

$11 Million
0.0% of portfolio
Chescapmanager LLC Baltimore, MD

1.7M
Shares

$8.31 Million
0.06% of portfolio
Farallon Capital Management LLC San Francisco, CA

1.56M
Shares

$7.59 Million
0.0% of portfolio
Disciplined Growth Investors Inc Minneapolis, MN

1.11M
Shares

$5.43 Million
0.01% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

1.11M
Shares

$5.41 Million
0.0% of portfolio

View Full List

About Cara Therapeutics, Inc.

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $262M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

More about CARA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account